Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Status:
Recruiting
Trial end date:
2027-11-15
Target enrollment:
Participant gender:
Summary
Open-label, non-randomized, phase II multi-centre controlled clinical trial.
51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in
this trial to evaluate the efficacy of the treatment (Atezolizumab + Induction chemotherapy
(CT) + CT-Radiotherapy) in terms of the Progression Free Survival at 12 months